WCM Investment Management LLC Buys 10,051 Shares of Pfizer Inc. (NYSE:PFE)

WCM Investment Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,964 shares of the biopharmaceutical company's stock after acquiring an additional 10,051 shares during the quarter. WCM Investment Management LLC's holdings in Pfizer were worth $3,176,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter valued at $30,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded up $0.13 during midday trading on Thursday, reaching $25.45. The company's stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,519,718. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock has a market cap of $144.66 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.91 and a beta of 0.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business has a 50-day moving average price of $23.62 and a 200-day moving average price of $24.83.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 EPS. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Bank of America increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. BMO Capital Markets lowered their price target on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Wolfe Research lifted their target price on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Finally, Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.